1 |
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 16, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
2 |
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 16, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
3 |
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 12, iss 3 (2016)
|
|
BASE
|
|
Show details
|
|
4 |
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 12, iss 3 (2016)
|
|
BASE
|
|
Show details
|
|
5 |
Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria
|
|
|
|
BASE
|
|
Show details
|
|
6 |
Revising the definition of Alzheimer's disease: a new lexicon
|
|
|
|
BASE
|
|
Show details
|
|
7 |
Revising the definition of Alzheimer's disease: a new lexicon ...
|
|
|
|
BASE
|
|
Show details
|
|
8 |
Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease
|
|
|
|
BASE
|
|
Show details
|
|
|
|